Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1990 34
1991 93
1992 76
1993 55
1994 50
1995 42
1996 42
1997 44
1998 40
1999 53
2000 60
2001 51
2002 30
2003 26
2004 36
2005 31
2006 43
2007 57
2008 64
2009 70
2010 81
2011 121
2012 156
2013 171
2014 179
2015 528
2016 787
2017 743
2018 673
2019 772
2020 739
2021 661
2022 737
2023 720
2024 303

Text availability

Article attribute

Article type

Publication date

Search Results

7,368 results

Results by year

Filters applied: . Clear all
Page 1
Targeting the MAPK Pathway in KRAS-Driven Tumors.
Drosten M, Barbacid M. Drosten M, et al. Cancer Cell. 2020 Apr 13;37(4):543-550. doi: 10.1016/j.ccell.2020.03.013. Cancer Cell. 2020. PMID: 32289276 Free article. Review.
Cancer vaccines: Targeting KRAS-driven cancers.
Zhang Y, Ma JA, Zhang HX, Jiang YN, Luo WH. Zhang Y, et al. Expert Rev Vaccines. 2020 Feb;19(2):163-173. doi: 10.1080/14760584.2020.1733420. Epub 2020 Mar 14. Expert Rev Vaccines. 2020. PMID: 32174221 Review.
Annual review of KRAS inhibitors in 2022.
Wang H, Chi L, Yu F, Dai H, Gao C, Si X, Wang Z, Liu L, Zheng J, Shan L, Liu H, Zhang Q. Wang H, et al. Eur J Med Chem. 2023 Mar 5;249:115124. doi: 10.1016/j.ejmech.2023.115124. Epub 2023 Jan 16. Eur J Med Chem. 2023. PMID: 36680986 Review.
Drugging RAS: Moving Beyond KRASG12C.
[No authors listed] [No authors listed] Cancer Discov. 2023 Dec 12;13(12):OF7. doi: 10.1158/2159-8290.CD-ND2023-0010. Cancer Discov. 2023. PMID: 37871268
Organoids Model Transcriptional Hallmarks of Oncogenic KRAS Activation in Lung Epithelial Progenitor Cells.
Dost AFM, Moye AL, Vedaie M, Tran LM, Fung E, Heinze D, Villacorta-Martin C, Huang J, Hekman R, Kwan JH, Blum BC, Louie SM, Rowbotham SP, Sainz de Aja J, Piper ME, Bhetariya PJ, Bronson RT, Emili A, Mostoslavsky G, Fishbein GA, Wallace WD, Krysan K, Dubinett SM, Yanagawa J, Kotton DN, Kim CF. Dost AFM, et al. Cell Stem Cell. 2020 Oct 1;27(4):663-678.e8. doi: 10.1016/j.stem.2020.07.022. Epub 2020 Sep 4. Cell Stem Cell. 2020. PMID: 32891189 Free PMC article.
Next batter up! Targeting cancers with KRAS-G12D mutations.
Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD. Zeissig MN, et al. Trends Cancer. 2023 Nov;9(11):955-967. doi: 10.1016/j.trecan.2023.07.010. Epub 2023 Aug 15. Trends Cancer. 2023. PMID: 37591766 Free article. Review.
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.
Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, Barve M, Velastegui K, Yan X, Shetty A, Der-Torossian H, Pant S. Bekaii-Saab TS, et al. J Clin Oncol. 2023 Sep 1;41(25):4097-4106. doi: 10.1200/JCO.23.00434. Epub 2023 Apr 26. J Clin Oncol. 2023. PMID: 37099736 Free PMC article.
Targeting Ras with protein engineering.
Tomazini A, Shifman JM. Tomazini A, et al. Oncotarget. 2023 Jul 1;14:672-687. doi: 10.18632/oncotarget.28469. Oncotarget. 2023. PMID: 37395750 Free PMC article. Review.
7,368 results